Clin Res Cardiol 98, Suppl 1, April 2009

V59 - Retroinfusion-facilitated inotropic AAV9-S100A1 gene therapy restores global cardiac function in a clinically relevant pig heart failure model
S. T. Pleger1, C. Shan1, J. Kziencek2, R. Bekeredjian1, W. J. Koch3, A. Remppis1, H. A. Katus1, O. J. Müller1, P. Most4
1Medizinische Klinik III, Kardiologie, Angiologie, Pulmonolgie, Universitätsklinikum Heidelberg, Heidelberg; 2Otto-Meyerhof-Zentrum, Universitätsklinikum Heidelberg, Heidelberg; 3Center for Translational Medicine, Philadelphia, USA; 4Laboratory for cardiac stem cell and gene therapy, Center For Translational Medicine, Department of Medicine, Division of Cardiology, Philadelphia, USA;
Background: Cardiac expression of the Ca2+-dependent inotropic protein S100A1 is decreased in human end-stage heart failure (HF) and cardiomyocyte-targeted viral-based S100A1 gene transfer rescued failing myocardium in small animal models in vivo and in vitro via improved systolic and diastolic sarcoplasmic reticulum Ca2+-handling. We therefore hypothesized that cardioselective AAV9-S100A1 gene therapy will improve cardiac performance in a large animal experimental HF model under clinical conditions.
Methods and Results:
Left ventricular (
LV) posterolateral myocardial infarction (MI) was induced in pigs by occlusion of the left coronary circumflex artery (LCX) and resulted in LV failure (HF) 2 weeks post-MI reflected by a 40% and 27% reduction in LV +dp/dt max. and EF, respectively, as assessed by LV catheterization and echocardiography. Post-MI HF pigs were then randomized for retroinfusion of AAV9-luciferase (luc; n=6, 1.5´
1013 total viral particles, tvp) and AAV9-S100A1 (S100A1; n=6, 1.5´1013 tvp) driven by a cardioselective promoter via the anterior cardiac vein while the left anterior descending artery (LAD) was temporarily occluded. 14 weeks after cardiac gene transfer, the S100A1-treated HF group showed significantly enhanced S100A1 protein expression (+46.7±17.9%, P<0.05 vs. control groups) in targeted remote LV myocardium and improved indices of cardiac performance and remodeling (luc vs. S100A1: +dp/dtmax: 983±81 vs. 1526±83 mmHg/s, EF: 39±2.1 vs. 61±3.7 %, P<0.05 S100A1 vs. luc, LV endsystolic diameter: luc 4.45±0.1 vs. S100A1 3.43 ±0.1 cm, P<0.05 S100A1 vs. luc, HR: 72±4 vs. 69±2, beats/min, P=n.s. S100A1 vs. luc). Importantly, analyses of renal, hepatic and hematopoetic function showed no alteration as assessed by unchanged transaminases, retention values and white blood cell counts compared to sham pigs.
Our translational study provides proof of concept that AAV9-S100A1 based HF gene therapy is feasible and restores cardiac performance in a large animal experimental HF model under clinical conditions. Next, certified toxicological analysis and different AAV9-S100A1 dosage protocols will be assessed to eventually advance to first phase I/II clinical studies determining therapeutic efficiency of cardiac S100A1 gene therapy in HF patients.